Introduction
“Pain is Inevitable; Suffering is Optional.” [M. Kathleen Casey].
Pain is a subjective multi-dimensional experience that is influenced by physiological stimuli and the emotional, cultural, environmental and social climate surrounding an individual. Chronic pain, usually defined as lasting 12 weeks or longer, is associated with increased psychological distress, decreased mobility, obesity, decreased physical function, social isolation, financial loss, and development of chronic disability [1]. Individuals with opioid dependence may have increased vulnerabilities that influence their experience of pain, including lowered pain thresholds [2, 3], increased social stress, psychological symptoms (depression, anxiety), financial strain, and decreased coping skills. More than one-third of patients on methadone maintenance therapy have chronic severe pain [4, 5]. In some cases, patients developed opioid addiction after being given opioid medication for the treatment of acute or chronic pain [6].
Since chronic pain lasts for months to years [7], a primary goal of treatment is to manage pain, rather than eliminate pain altogether. This is true in patients with and without addictive diseases, but is particularly important to establish with patients with addiction. Pain is associated with increased odds of opioid misuse in opioid dependent persons [8]. Managing expectations of both clinician and patient is a mainstay of treatment. A second principle is to address the individual symptoms contributing to and resulting from chronic pain and those of importance to the patient. Lastly, self-management of pain symptoms and sequelae should be integrated into all aspects of pain treatment. Very little evidence exists specifically for treating pain in patients with addiction of any type, but principles of pain treatment in the general population are applicable to patients with opioid dependence.
The five pillars of treatment include
Improving psychosocial engagement. Cognitive behavioral therapy as well as other therapies may be helpful for pain [9, 10] but has not been proven to be helpful in opioid dependence [11-13]. Mindfulness- based therapies have been studied for pain management but have shown little efficacy to date [14, 15]. Developing a specific plan for socialization, whether it be participation in regular substance abuse treatment group, 12-step programs or other activity (perhaps with family or friends) is key to keeping the patient engaged. In particular, with pain and disability, finding a way to feel useful and engaged is essential to recovery from chronic pain. Case management or social work referral may help patients identify potential aid for financial or housing stress.
Physical mobility and function. A variety of methods can be used for patients to improve and maintain physical function. Increasing activity can improve mood [16, 17], increase weight loss [18], prevent deconditioning and improve pain related disability [19]. Physical therapy and other modalities (yoga) improve pain outcomes [20-28].
Weight loss in persons with obesity. A combination of diet and exercise for weight loss can improve pain symptoms and function [29].
Engagement with substance use treatment and/or relapse prevention. To treat pain optimally, patients also need to focus on their substance use, including taking accountability for their use. In the experience of the authors, some patients with substance use disorders may focus so much on the pain that they avoid doing the cognitive and emotional work required to recover from substance use problems. Full commitment to substance use disorder treatment is central to success of managing pain.
Medications. Medications can be used to both decrease the pain sensation but also to treat the other symptoms that occur with chronic pain. Medications from different classes of medicine may be synergistic to relieve symptoms. Opioid medications are not recommended for use to treat chronic pain in patients with opioid dependence. The exception would be a patient with terminal cancer, for whom it would be appropriate. Opioid agonist treatment for addiction may have benefits for chronic pain [30]. Opioids are appropriate for acute pain in an inpatient medical setting.
TREATMENT
Diet and lifestyle | |
|
|
Pharmacologic treatment | |
|
|
| |
WHO’s Pain Relief Ladder (WHO, 1986) | |
|
Simple Analgesics
Acetaminophen has been shown to be better than placebo in patients with chronic pain due to osteoarthritis of the knee with respect to pain control, but not superior to NSAIDs, Class I [39]. However, Acetaminophen can be considered first-line for chronic pain because it has a better side effect profile than NSAIDs, Class I [40].
Acetaminophen: | |
Standard dosage: | 650 mg Q6 hours (Max 2000 mg if cirrhosis or ≥ 3 alcoholic drinks/day) |
Contraindications: | Patients with liver impairment and those with daily, regular alcohol intake |
Main drug interactions: | Anticonvulsants, barbiturates, carbamazepine may increase the metabolism of acetaminophen; isoniazid, prilocaine. Acetaminophen increases the effects of warfarin with doses > 1.5-2g/day. Acute excessive intake of alcohol can lead to increased risk of acetaminophen hepatotoxicity. |
Main side effects : | Occasional skin rash and other allergic reactions. Acute overdose can cause fatal hepatic injury. |
Special points: | Well tolerated. Can be combined with other analgesics. Effective analgesic- antipyretic agent, but its anti-inflammatory activity is weak. When used as part of multimodal analgesia, can reduce the amount of opioids needed to control pain. |
Cost: | Low cost |
Non-Steroidal Anti-Inflammatory (NSAID)
This category of medications includes a number of over-the-counter and prescription options. Doses suggested are prescription level. This list is a sampling of widely used options. For all NSAIDs, urticaria, or allergic-type reactions following aspirin or other NSAIDS is a contraindication to use. In a systematic review of 65 RCTs including 11,237 patients, strong evidence was found to support the efficacy of NSAIDs and COX-2 inhibitors for acute and chronic low back pain, Class I [41]. All NSAIDs were found to have similar efficacy.
Naproxen: | |
Standard dosage: | 500 mg Q12 hours or 500 Q AM plus 250 BID (Max 1000 mg/24 hours) |
Contraindications: | Full-dose naproxen is not recommended in older adults because of its long half-life |
Main drug interactions: | Avoid combining NSAIDS. May interact with drugs prescribed for cardiac disease including anti-hypertensive, anti-platelet and anti-coagulant medications. |
Main side effects: | GI toxicity, renal toxicity, platelet dysfunction. |
Special points: | First line NSAID. |
Cost: | Low cost |
Ibuprofen: | |
Standard dosage: | 600 mg every 6 hours (Max 2400 mg/24 hours) |
Main drug interactions: | ACE-inhibitors, aspirin, lithium, warfarin |
Main side effects: | GI toxicity, renal toxicity, platelet dysfunction |
Special points: | Second line NSAID. Ibuprofen can interfere with the cardioprotective effect of aspirin, so it should be taken 30 minutes to 2 hours after aspirin intake or at least 8 hours before. Pregnancy Category C. |
Cost: | Low cost |
Piroxicam: | |
Standard dosage: | 10mg once daily |
Contraindications: | Avoid full dose in elderly due to its long half-life and risk of GI toxicity |
Main drug interactions: | ACE-Inhibitors, MAOIs, aspirin, warfarin |
Main side effects: | High risk of GI toxicity, renal toxicity, platelet dysfunction |
Special points: | Second line NSAID. Pregnancy Category C |
Cost: | Moderate cost |
Diclofenac: | |
Standard dosage: | 18 or 35 mg ORALLY 3 times daily |
Main drug interactions: | Concomitant use with other NSAIDS may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation). |
Main side effects: | Increased liver function test |
Special points: | Second line NSAID. Pregnancy category C |
Cost: | High cost |
Indomethacin: | |
Standard dosage: | maximum recommended oral or rectal dose is 200 mg/day |
Main drug interactions: | Concurrent use of other NSAIDs may result in enhanced gastrointestinal adverse effects (peptic ulcers, gastrointestinal bleeding and/or perforation). |
Main side effects: | Dizziness, headache, GI toxicity, increased liver enzymes, renal toxicity |
Special points: | Use lowest effective dose for shortest possible duration this is to be used in short term only. |
Cost: | Low cost |
COX-2 Inhibitors
This subset of NSAID category of medications have less gastrointestinal side effects. Some formulations have been found to increase risk for cardiovascular disease and have been removed from the market. Urticaria or allergic-type reaction to aspirin or other NSAIDS is a contraindication to use. In a randomized controlled trial of 446 patients with chronic low back pain, a COX-2 inhibitor was found to be comparable to NSAIDs for pain relief, Class II [42]. In a systematic review of patients with chronic low back pain, two randomized trials compared COX-2 inhibitors with traditional NSAIDs, and no statistically significant difference was found between the two treatments, Class I [43].
Nabumetone | |
Standard dosage: | Arthritis 1000-2000mg PO daily. May be given once or twice daily. Max dose 2000 mg/day. |
Contraindications: | Allergy or hypersensitivity to aspirin or NSAIDs. |
Main side effects: | Edema, pruritus, rash, constipation, diarrhea, headache, tinnitus |
Special points: | The drug is best taken with food or milk. Patient should not drink alcohol while taking this drug. |
Cost: | Moderate cost |
Celecoxib | |
Standard dosage: | 200-400 mg daily in two doses. |
Contraindications: | Asthma, pruritis, rhinorrhea, or other reaction after aspirin or other NSAID. Up to 21% of patients with a hypersensitivity to NSAIDs also have a hypersensitivity to COX-2 inhibitors [44]. |
Main drug interactions: | Concurrent use of NSAIDs may result in enhanced gastrointestinal toxicity. |
Main side effects: | Hypertension, diarrhea, headache |
Special points: | Instruct patients on higher doses (400 mg twice daily) to take drug with food. Lower doses may be taken with or without food. Tell patient to avoid drinking alcohol and smoking, as this may increase risk for gastrointestinal bleeding. |
Cost: | Moderate cost |
Muscle Relaxants
Of note, carisoprodol (Soma) is a muscle relaxant that is metabolized to a barbiturate and should not be prescribed for patients with opioid dependence. Cyclobenzaprine is the best studied muscle relaxant. A meta-analysis of 5 RCTs showed that cyclobenzaprine had efficacy for treating pain due to fibromyalgia [45], and later Kroenke et al. found that 21 RCTs show that cyclobenzaprine is effective for pain relief in patients with fibromyalgia [40]. A recent randomized trial of 36 patients showed that low-dose cyclobenzaprine improved pain associated with FM, Class II [46].
Cyclobenzaprine: (Flexeril) | |
Standard dosage: | immediate release: 5 mg TID, may increase to 10 mg TID; extended release: 15 mg PO daily. |
Contraindications: | Cardiac conduction disturbances, CHF, hypersensitivity, hyperthyroidism, MI (or acute recovery period). |
Main drug interactions: | MAOIs, TCAs, bupropion phenothiazine, clonidine |
Main side effects: | Dizziness, sedation, dry mouth, orthostatic hypotension. |
Special points: | Generally well-tolerated but have sedative effects that may be additive to other centrally-acting drugs, including opioids. Muscle relaxants are not recommended in older adults as this age group has increased sensitivity to the anticholinergic and sedating effects of the drugs, and the muscle relaxant effect may contribute to falls [47]. |
Cost: | Low cost |
Anti-Seizure Medications
Anti-seizure medications, in particular gabapentin and pregabalin, are FDA approved to treat neuropathic pain. A Cochrane Review in 2013 found that gabapentin and pregabalin were supported by 2nd tier evidence for the treatment of diabetic neuropathy and post-herpetic neuralgia, Class I [48]. Evidence also supported the use of pregabalin in fibromyalgia for pain [48].
Gabapentin: (Neurontin) | |
Standard dosage: | Titrate up to 900-1200mg TID |
Contraindications: | Kidney disease, depression, pregnancy. |
Main drug interactions: | Antacids |
Main side effects: | Sedation, dizziness, unsteadiness, and nausea. |
Special points: | Adverse effects usually lessen with time. Reports of abuse exist for gabapentin at high doses. |
Cost: | Moderate cost |
Pregabalin:(Lyrica) | |
Standard dosage: | 300-450 mg QD, divided into BID doses |
Contraindications: | Caution in elderly, depressed, renal impairment, heavy alcohol consumption |
Main drug interactions: | Pioglitazone (Actos) and rosiglitazone (Avandia) |
Main side effects: | sedation, dizziness, unsteadiness, and nausea |
Special points: | Adverse effects usually lessen with time. Approved for treatment of fibromyalgia. Should be considered the first-line drug for the treatment of post-herpetic neuralgia and other neuropathies unless a co-morbid depression suggests that a tricyclic antidepressant should be tried first [49, 50]. |
Cost: | High Cost |
Tricyclic Antidepressants (TCAs)
TCAs have been shown to be more effective in fibromyalgia than other anti-depressants as well as other treatment options [51, 52]. In addition to the two well-studied TCAs listed below, a number of other TCAs are likely to be equally effective.
Amitriptyline: (Elavil) | |
Standard dosage: | Start at 10-25 mg at bedtime; titrate to 100 mg (max 50 mg if taking an SSRI/SNRI) |
Contraindications: | TCA allergies |
Main drug interactions | MAOIs, St. John’s Wort, clonidine. Use with caution with other medications that cause QTc prolongation |
Main side effects: | sedation, orthostatic hypotension, urinary retention, and dry mouth. |
Special points: | Avoid in older adults. |
Cost: | Low cost |
Nortriptyline:(Pamelor) | |
Standard dosage: | Start at 10-25 mg, titrate to 100 mg (max 50 mg if taking an SSRI/SNRI) |
Contraindications: | TCA allergies |
Main drug interactions: | Alcohol can increase side effects. Use with caution with other medications that cause QTc prolongation. |
Main side effects: | sedation, orthostatic hypotension, and dry mouth |
Special points: | Try at least 2 TCAs but avoid in older adults (65+ years). It has less hypotension than Amitriptyline. |
Cost: | Low cost |
Selective Serotonin Reuptake Inhibitors (SSRIs)
Fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, escitalopram | |
SSRIs have been used for chronic pain, although have less efficacy than TCAs for fibromyalgia. The beneficial effect on chronic pain may be more on the co-occurring symptoms, in particular depression, associated with chronic pain rather than the pain itself. In a trial of 12 weeks of treatment with antidepressant medication (n = 123) or usual care (n = 127), at 12 months patients receiving the intervention had greater reduction in depression and pain, Class I [53]. | |
Standard dosage: | Dosing varies based on the SSRI. |
Contraindications: | hypersensitivity to sertraline, fluoxetine, paroxetine, or citalopram. |
Main drug interactions: | disulfiram, MAOI within 14 days, pimozide |
Main side effects: | sexual dysfunction, drowsiness, weight gain, insomnia, anxiety, dizziness, headache, dry mouth, blurry vision, nausea, rash, tremor, constipation. |
Cost: | Moderate cost (variable, depending on which medication) |
Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
This class of medications treats both mood and a variety of other disorders- fibromyalgia, neuropathic pain, and menstrual syndromes. Duloxetine was found to be effective for treating pain due to fibromyalgia in a recent Cochrane review, Class I [54].
Venlafaxine: (Effexor) | |
Standard dosage: | Start at 37.5 mg and titrate up to effective dose, with max at 225mg QD |
Contraindications: | Glaucoma, heart disease, HTN, mania, seizure disorders |
Main drug interactions: | MAOIs, SSRIs St John’s Wort |
Main side effects: | Dizziness, drowsiness, nausea and vomiting, dry mouth. |
Special points: | Better adverse event profile than TCAs [55]. Use cautiously in patients with high CV risk. Should not stop abruptly. Can cause dose-related hypertension, and, if appropriate, blood pressure (BP) monitoring should be done during initiation of treatment. |
Cost: | Low cost (generic available) |
Duloxetine (Cymbalta) | |
Standard dosage: | titrate up to 60mg QD |
Contraindications: | An increase in hepatotoxicity has been linked to the use of duloxetine in individuals with pre-existing liver disease, suggesting that the drug may aggravate the disease |
Main drug interactions: | MAOIs, selegiline, tranylcypromine |
Main side effects: | dizziness, fatigue, and dry mouth. |
Special points: | FDA-approved for fibromyalgia and diabetic neuropathy. Side effects can be reduced by starting at 30 mg daily for 1 week and then increasing to 60 mg daily. Should not be stopped abruptly. Numerous trials have shown efficacy in decreasing pain due to osteoarthritis [56, 57]. Better adverse event profile than TCAs [55]. |
Cost: | High cost (still on patent) |
Dual Mechanism Opioids
These medications have both mu-opioid agonist and nor-epinephrine (+/−) serotonin reuptake inhibitor properties. This may improve inhibitory processes in the mid-brain to decrease pain signals. Both have abuse and addiction potential.
Tramadol: | |
Standard dosage: | 100 mg PO once daily; titrate up by 100 mg every 2-3 days as needed for moderate pain. For severe pain, 100 mg PO daily, titrate up by 100 mg every 5 days as needed with a maximum of 300 mg /day. |
Contraindications: | Hypercapnia, acute or severe bronchial asthma, respiratory depression, hypersensitivity to opioids. |
Main drug interactions: | Acute intoxication with alcohol, hypnotics, narcotics, centrally acting analgesics, or psychotropic drugs (may worsen CNS and respiratory depression). |
Main side effects: | Flushing, pruritis, constipation, nausea, vomiting, dizziness, headache, insomnia, somnolence. Rarely, seizure, dyspnea, pancreatitis. |
Special points: | Patients should be tapered if they are on tramadol chronically. |
Cost: | Low cost |
Tapentadol: | |
Standard dosage: | For severe chronic pain, 50 mg PO extended release q12h. Titrate up by 50 mg q3d, up to therapeutic range of 100-250 mg PO q12h. Maximum dose of 500 mg/day. |
Contraindications: | Hypercapnia, bronchial asthma, hypersensitivity to tapentadol, GI obstruction, respiratory depression. |
Main drug interactions: | MAOIs, sedatives. |
Main side effects: | Constipation, nausea, vomiting, dizziness, Headache, somnolence, hypotension, left bundle branch block, anaphylaxis, seizure, respiratory depression. |
Special points: | Seizure potential |
Cost: | Moderate cost |
Opioids
Although opioids are a common treatment for chronic pain, they are not recommended for patients with active addiction of any type. They can be cautiously recommended for patients in stable recovery, although even then have to be closely monitor. Use of opioids may become problematic in patients with prior addiction. High quality studies on use of opioids for chronic non-cancer pain are not available, and most available trials of opioids for chronic pain are limited by the exclusion of patients with addiction, sponsorship by pharmaceutical industry, small sample sizes, and short duration. A Cochrane review combining the largest trials with 8-13 month follow up found that only 44% of patients treated with opioids experienced a 50% reduction in pain [58]. In certain patients, the underlying pain condition may warrant use of opioids, in which case, they should be under the care of someone with both addiction and pain expertise who has the ability to do close monitoring with pills counts, and urine drug testing.
Two opioids used in the treatment of opioid dependence have potential analgesic properties. A study of patients with addiction on chronic opioid therapy who were randomized to low dose methadone or buprenorphine/naloxone produced moderate analgesia [30].
Methadone: | |
Standard Dosage: |
For chronic pain treatment: methadone should be started at very low doses and increased slowly over weeks. Since the analgesic half-life is 6-8 hours, it should be given 3-4 times daily. It can be started at 2.5-5 mg 3-4 times per day, with increases done at weekly intervals. For chronic pain, 30-60 mg total daily dose is typical range. For opioid dependence, methadone should be prescribed by programs and providers with federal licensure to treat opioid dependence with methadone. It should not be initiated for this purpose without enrollment in such a program. For opioid dependence, methadone is started at a dose of 20-300mg/day, with a maximum dose of 30 mg [59, 60]. An additional 10 mg can be given on the first day if withdrawal symptoms persist hours later. If the initial dose of methadone is too high, patients may experience respiratory depression, urinary retention, edema, and abdominal distension. After the first day, the dose is then increased at 5-10 mg increments daily until 60-80 mg/day is reached. Dose increases after 80 mg /day should proceed slowly based on the individual patient’s cravings and withdrawal symptoms. Most patients are stable on doses 80-120mg/day [59]. |
Main drug interactions: | Phenytoin, phenobarbital, carbamazepine, rifamycins, benzodiazepines. Concomitant use with MAOI’s can induce serotonin syndrome. |
Main side effects: | Constipation, sedation, potential QTc prolongation. |
Special points: | Methadone serum half-life ranges from 20-100 hours, and is dosed every 24 hours for opioid replacement therapy. The analgesic effects of methadone are much shorter (6-8 hours) and it is given more frequently for pain relief. . The peak respiratory depression due to methadone occurs at 12-14 hours after the dose, and lasts longer than the analgesic effects, which contributes to the risk of overdose [60]. Respiratory depression has been implicated as the cause of death in most methadone-related deaths [60]. Even if the patient has a history of opioid tolerance, it should be started at low doses and increased slowly. If the patient is already taking other opioids, those medications can be tapered while the methadone is being titrated up. It can also cause QT prolongation, particularly at higher doses and when combined with other medications with QT prolongation effects. No neurotoxic metabolites. Chronic low-dose methadone may be safe for pain and have the side benefit of suppressing opioid cravings [30]. |
Cost: | Low cost |
Partial Opioid Agonists
Buprenorphine: | |
Standard dosage: | 8-16 mg sublingual daily for opioid agonist treatment for opioid dependence, but doses as low as 2 mg a day or as high as 32 mg a day have been used successfully |
Contraindications: | Concurrent use of other opioids. Attaches tightly to mu receptor, limiting the ability of other opioids to act |
Main drug interactions: | CNS depressants, azole antifungals, macrolide antibiotics, HIV antivirals, and protease inhibitors |
Main side effects: | Taste aversion, sedation in opioid naïve individuals. |
Special points: | Has a ceiling effect at the mu receptor. Respiratory depression not easily reversed with naloxone. It has some analgesic properties, and preliminary data suggests it can be used to decrease pain (off-label) and to concomitantly treat opioid dependence [30]. Because the analgesic effects are shorter than the serum half-life, analgesic dosing should be every 6 hours |
Cost: | High cost |
Topical medications
Topical medications have shown efficacy for decreasing musculoskeletal pain and often have fewer side effects than systemic therapy. Lidocaine has been proven to be effective for chronic pain due to post-herpetic neuralgia [61] and diabetic neuropathy [62], and limited evidence exists for the use of lidocaine with other chronic pain conditions, Class I [62]. Topical capsaicin is useful as an adjunct to other medications for chronic pain patients, Class I [63]. Topical NSAIDs, such as diclofenac, have also proven efficacy for osteoarthritis, but not for chronic low back pain [64].
Capsaicin: | |
Standard dosage: | 3-4 times per day for arthritis and musculoskeletal pain |
Contraindications: | Specific contraindications have not been determined |
Main drug interactions: | None |
Main side effects: | Erythema, pain, rash, or pruritis of application site; nausea; nasopharyngitis; hypertension |
Special points: | Treatment area may be heat-sensitive, and patient should not apply cream directly before bathing, swimming, sun bathing, or exercise. |
Cost: | Low cost |
Lidocaine Cream and Patch (Lidoderm): | |
Standard dosage: | 5% ointment, maximum dose of 17-20 g of ointment daily; apply up to 3 patches topically at one time, for up to 12 hours within a 24-hour period. |
Contraindications: | Hypersensitivity to local anesthetics of the amide type. |
Main drug interactions: | None for topical lidocaine. |
Main side effects: | Rare for topical application. |
Cost: | High cost patch, low cost cream |
BenGay (Camphor 4%, Menthol 10%, Methylsalicylate 30%): | |
Standard dosage: | Apply to affected area 3-4 times daily |
Contraindications: | hypersensitivity to Camphor, hypersensitivity to peppermint, menthol, or any other member of the mint family, topical application should not be used on the face or chest of infants or small children or on open skin areas. |
Main drug interactions: | No drug interaction data available. |
Main side effects: | Nausea, vomiting, warmth, headache, confusion, vertigo, delirium, hallucinations, tremors, elevated LDH, contact eczema, contact dermatitis. |
Cost: | Low cost |
Diclofenac (topical) | |
Standard dosage: | (1% gel) 2-4 gm applied daily around joint (1.5% solution) 10 drops around affected joints 4 times daily |
Contraindications: | NSAID or aspirin allergy |
Main drug interactions: | Concomitant use of Ketoralac (Strong NSAID) or Cyclosporine |
Main side effects: | Local site reaction, blood coagulation disorder [65] |
Cost: | High cost |
Physical/speech therapy and exercise | |
• Exercise, including physical therapy, aerobic exercise, and yoga, has been evaluated to treat various chronic pain syndromes, including fibromyalgia and chronic low back pain. Although there is currently no evidence to support the use of exercise in patients with concurrent opioid dependence, the exercise interventions below will likely have a positive effect on these patients. |
|
Physical Therapy | |
|
|
Yoga | |
|
|
Other treatments | |
• Clinical trials have investigated acupuncture, Cognitive Behavioral Therapy (CBT), and massage as effective treatment options for chronic pain in general populations, with limited evidence in populations with addiction or opioid dependence. Mindfulness and qigong have not been shown to be effective for pain conditions. CBT, while effective for pain, has not been shown to be effective for addiction. It is not clear how it would work in populations with opioid dependence. |
|
Acupuncture for Chronic Pain | |
|
|
Cognitive Behavioral Therapy (CBT) | |
|
|
Mindfulness | |
|
|
Qigong | |
• Qigong is a form of Chinese medicine that includes deep breathing exercises and meditation. Qigong has been investigated as a treatment for pain due to fibromyalgia. In a systematic review of 7 articles and 395 fibromyalgia patients, Lauche et al. found low-quality evidence to support the use of qigong to improve pain, quality of life, and sleep. No evidence was found for superiority of qigong over usual care of patients with fibromyalgia, Class I [72]. |
|
Massage | |
|
|
Multidisciplinary Therapy | |
• Multidisciplinary treatment for pain conditions has been shown in individual trials, meta-analyses and systematic reviews to be more effective than control conditions [75]. Inpatient treatment programs tend to be more intense that outpatient but do not have strong advantage over outpatient treatment when accounting for intensity. In particular, chronic back pain benefit from multidisciplinary treatment. A Cochrane review of multidisciplinary treatment for fibromyalgia showed mixed results without evidence of efficacy in low quality studies [76]. Behavioral treatment and stress reduction as well as physical training appear to be beneficial aspects of multidisciplinary treatment [76]. Class II |
Opinion statement.
Chronic pain may last for months to years, and is often heightened by co-morbid opioid dependence; thus, setting realistic expectations for both patient and physician is a key step in formulating treatment plans. Chronic pain is influenced by psychological, social and environmental factors in addition to somatic pathology, and thus, treatment needs to encompass more than just analgesia. The specific treatments should address contributors to and sequelae of chronic pain and addiction (e.g. social isolation, physical disability, depression, anxiety, obesity, financial stress, housing instability) and include multimodal interventions: psychosocial engagement, physical mobility and conditioning, weight loss, substance use treatment, and medications. Psychosocial treatments include evidence-based cognitive behavioral therapies, substance abuse treatment groups, 12-step programs and other social activities. Physical mobility and conditioning can be accomplished with physical therapy, yoga, or other exercise programs, and are essential to avoid loss of function and a negative functional spiral. In the setting of obesity, diet in combination with exercise can decrease pain and improve function. Substance abuse treatment is essential for patients with comorbid pain and opioid dependence. Opioid replacement therapies may have some added analgesic benefit. Medication can help decrease the pain level and alleviate some of the complicating conditions but is unlikely to be effective used in isolation. Opioid analgesics are generally not recommended in cases of patient with opioid dependence because of mixed evidence for efficacy and high risk.
Footnotes
Compliance with Ethics Guidelines Conflict of interest Jane Liebschutz, Donna Beers and Allison Lange declare that they have no conflicts of interest.
Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as:
*of importance
- 1.Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. Jama. 2003;290(18):2443–54. doi: 10.1001/jama.290.18.2443. [DOI] [PubMed] [Google Scholar]
- 2.Compton P, Charuvastra VC, Ling W. Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent. Drug Alcohol Depend. 2001;63(2):139–46. doi: 10.1016/s0376-8716(00)00200-3. [DOI] [PubMed] [Google Scholar]
- 3.Pud D, Cohen D, Lawental E, Eisenberg E. Opioids and abnormal pain perception: New evidence from a study of chronic opioid addicts and healthy subjects. Drug Alcohol Depend. 2006;82(3):218–23. doi: 10.1016/j.drugalcdep.2005.09.007. [DOI] [PubMed] [Google Scholar]
- 4.Barry DT, Beitel M, Garnet B, Joshi D, Rosenblum A, Schottenfeld RS. Relations among psychopathology, substance use, and physical pain experiences in methadone-maintained patients. J Clin Psychiatry. 2009;70(9):1213–8. doi: 10.4088/JCP.08m04367. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Rosenblum A, Joseph H, Fong C, Kipnis S, Cleland C, Portenoy RK. Prevalence and characteristics of chronic pain among chemically dependent patients in methadone maintenance and residential treatment facilities. Jama. 2003;289(18):2370–8. doi: 10.1001/jama.289.18.2370. [DOI] [PubMed] [Google Scholar]
- 6.Tsui JI, Herman DS, Kettavong M, Alford D, Anderson BJ, Stein MD. Physician introduction to opioids for pain among patients with opioid dependence and depressive symptoms. J Subst Abuse Treat. 2010;39(4):378–83. doi: 10.1016/j.jsat.2010.06.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Ang DC, Bair MJ, Damush TM, Wu J, Tu W, Kroenke K. Predictors of pain outcomes in patients with chronic musculoskeletal pain co-morbid with depression: results from a randomized controlled trial. Pain Med. 2010;11(4):482–91. doi: 10.1111/j.1526-4637.2009.00759.x. [DOI] [PubMed] [Google Scholar]
- 8.Tsui JI, Cheng DM, Coleman SM, Blokhina E, Bridden C, Krupitsky E, et al. Pain is associated with heroin use over time in HIV-infected Russian drinkers. Addiction. 2013;108(10):1779–87. doi: 10.1111/add.12274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Lamb SE, Hansen Z, Lall R, Castelnuovo E, Withers EJ, Nichols V, et al. Group cognitive behavioural treatment for low-back pain in primary care: a randomised controlled trial and cost-effectiveness analysis. Lancet. 2010;375(9718):916–23. doi: 10.1016/S0140-6736(09)62164-4. [DOI] [PubMed] [Google Scholar]
- 10.Williams AC, Eccleston C, Morley S. Psychological therapies for the management of chronic pain (excluding headache) in adults. Cochrane Database Syst Rev. 2012;14(11) doi: 10.1002/14651858.CD007407.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011;5(10) doi: 10.1002/14651858.CD004147.pub4. [DOI] [PubMed] [Google Scholar]
- 12.Fiellin DA, Barry DT, Sullivan LE, Cutter CJ, Moore BA, O’Connor PG, et al. A randomized trial of cognitive behavioral therapy in primary care-based buprenorphine. Am J Med. 2013;126(1):005. doi: 10.1016/j.amjmed.2012.07.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mayet S, Farrell M, Ferri M, Amato L, Davoli M. Psychosocial treatment for opiate abuse and dependence. Cochrane Database Syst Rev. 2005;25(1) doi: 10.1002/14651858.CD004330.pub2. [DOI] [PubMed] [Google Scholar]
- 14.Schmidt S, Grossman P, Schwarzer B, Jena S, Naumann J, Walach H. Treating fibromyalgia with mindfulness-based stress reduction: results from a 3-armed randomized controlled trial. Pain. 2011;152(2):361–9. doi: 10.1016/j.pain.2010.10.043. [DOI] [PubMed] [Google Scholar]
- 15.Wong SY, Chan FW, Wong RL, Chu MC, Kitty Lam YY, Mercer SW, et al. Comparing the effectiveness of mindfulness-based stress reduction and multidisciplinary intervention programs for chronic pain: a randomized comparative trial. Clin J Pain. 2011;27(8):724–34. doi: 10.1097/AJP.0b013e3182183c6e. [DOI] [PubMed] [Google Scholar]
- 16.Herring MP, O’Connor PJ, Dishman RK. The effect of exercise training on anxiety symptoms among patients: a systematic review. Arch Intern Med. 2010;170(4):321–31. doi: 10.1001/archinternmed.2009.530. [DOI] [PubMed] [Google Scholar]
- 17.Martin CK, Church TS, Thompson AM, Earnest CP, Blair SN. Exercise dose and quality of life: a randomized controlled trial. Arch Intern Med. 2009;169(3):269–78. doi: 10.1001/archinternmed.2008.545. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Hankinson AL, Daviglus ML, Bouchard C, Carnethon M, Lewis CE, Schreiner PJ, et al. Maintaining a high physical activity level over 20 years and weight gain. Jama. 2010;304(23):2603–10. doi: 10.1001/jama.2010.1843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Rainville J, Hartigan C, Martinez E, Limke J, Jouve C, Finno M. Exercise as a treatment for chronic low back pain. Spine J. 2004;4(1):106–15. doi: 10.1016/s1529-9430(03)00174-8. [DOI] [PubMed] [Google Scholar]
- 20.Hayden JA, van Tulder MW, Malmivaara A, Koes BW. Exercise therapy for treatment of non-specific low back pain. Cochrane Database Syst Rev. 2005;20(3) doi: 10.1002/14651858.CD000335.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hayden JA, van Tulder MW, Tomlinson G. Systematic review: strategies for using exercise therapy to improve outcomes in chronic low back pain. Ann Intern Med. 2005;142(9):776–85. doi: 10.7326/0003-4819-142-9-200505030-00014. [DOI] [PubMed] [Google Scholar]
- 22.Busch AJ, Barber KA, Overend TJ, Peloso PM, Schachter CL. Exercise for treating fibromyalgia syndrome. Cochrane Database Syst Rev. 2007;17(4) doi: 10.1002/14651858.CD003786.pub2. [DOI] [PubMed] [Google Scholar]
- 23.Nuesch E, Hauser W, Bernardy K, Barth J, Juni P. Comparative efficacy of pharmacological and non-pharmacological interventions in fibromyalgia syndrome: network meta-analysis. Ann Rheum Dis. 2013;72(6):955–62. doi: 10.1136/annrheumdis-2011-201249. [DOI] [PubMed] [Google Scholar]
- 24.Hauser W, Thieme K, Turk DC. Guidelines on the management of fibromyalgia syndrome - a systematic review. Eur J Pain. 2010;14(1):5–10. doi: 10.1016/j.ejpain.2009.01.006. [DOI] [PubMed] [Google Scholar]
- 25.Cramer H, Lauche R, Haller H, Dobos G. A systematic review and meta-analysis of yoga for low back pain. Clin J Pain. 2013;29(5):450–60. doi: 10.1097/AJP.0b013e31825e1492. [DOI] [PubMed] [Google Scholar]
- 26.Sherman KJ, Cherkin DC, Wellman RD, Cook AJ, Hawkes RJ, Delaney K, et al. A randomized trial comparing yoga, stretching, and a self-care book for chronic low back pain. Arch Intern Med. 2011;171(22):2019–26. doi: 10.1001/archinternmed.2011.524. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Tilbrook HE, Cox H, Hewitt CE, Kang’ombe AR, Chuang LH, Jayakody S, et al. Yoga for chronic low back pain: a randomized trial. Ann Intern Med. 2011;155(9):569–78. doi: 10.7326/0003-4819-155-9-201111010-00003. [DOI] [PubMed] [Google Scholar]
- 28.Cramer H, Lauche R, Langhorst J, Dobos G. Yoga for rheumatic diseases: a systematic review. Rheumatology. 2013;52(11):2025–30. doi: 10.1093/rheumatology/ket264. [DOI] [PubMed] [Google Scholar]
- 29.Senna MK, Sallam RA, Ashour HS, Elarman M. Effect of weight reduction on the quality of life in obese patients with fibromyalgia syndrome: a randomized controlled trial. Clin Rheumatol. 2012;31(11):1591–7. doi: 10.1007/s10067-012-2053-x. [DOI] [PubMed] [Google Scholar]
- *30.Neumann AM, Blondell RD, Jaanimagi U, Giambrone AK, Homish GG, Lozano JR, et al. A preliminary study comparing methadone and buprenorphine in patients with chronic pain and coexistent opioid addiction. J Addict Dis. 2013;32(1):68–78. doi: 10.1080/10550887.2012.759872. This small randomized trial compared methadone and buprenorphine as treatments for chronic pain in patients with opioid dependence.
- 31.Christensen R, Bartels EM, Astrup A, Bliddal H. Effect of weight reduction in obese patients diagnosed with knee osteoarthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2007;66(4):433–9. doi: 10.1136/ard.2006.065904. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Messier SP, Loeser RF, Miller GD, Morgan TM, Rejeski WJ, Sevick MA, et al. Exercise and dietary weight loss in overweight and obese older adults with knee osteoarthritis: the Arthritis, Diet, and Activity Promotion Trial. Arthritis Rheum. 2004;50(5):1501–10. doi: 10.1002/art.20256. [DOI] [PubMed] [Google Scholar]
- 33.Roddy E, Zhang W, Doherty M. Aerobic walking or strengthening exercise for osteoarthritis of the knee? A systematic review. Ann Rheum Dis. 2005;64(4):544–8. doi: 10.1136/ard.2004.028746. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Nicholas MK, Asghari A, Blyth FM, Wood BM, Murray R, McCabe R, et al. Self-management intervention for chronic pain in older adults: a randomised controlled trial. Pain. 2013;154(6):824–35. doi: 10.1016/j.pain.2013.02.009. [DOI] [PubMed] [Google Scholar]
- 35.Gustavsson C, Denison E, von Koch L. Self-management of persistent neck pain: two-year follow-up of a randomized controlled trial of a multicomponent group intervention in primary health care. Spine (Phila Pa 1976) 2011;36(25):2105–15. doi: 10.1097/BRS.0b013e3182028b04. [DOI] [PubMed] [Google Scholar]
- 36.Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226–35. doi: 10.1016/S0140-6736(11)60402-9. [DOI] [PubMed] [Google Scholar]
- 37.Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, Gabapentin, or Their Combination for Neuropathic Pain. New England Journal of Medicine. 2005;352(13):1324–34. doi: 10.1056/NEJMoa042580. doi:doi:10.1056/NEJMoa042580. [DOI] [PubMed] [Google Scholar]
- 38.Organization WH. Cancer Pain Relief with a guide to opioid availability. World Health Organization; Geneva: 1996. [Google Scholar]
- 39.Towheed TE, Maxwell L, Judd MG, Catton M, Hochberg MC, Wells G. Acetaminophen for osteoarthritis. Cochrane Database Syst Rev. 2006;25(1) doi: 10.1002/14651858.CD004257.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Kroenke K, Krebs EE, Bair MJ. Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews. Gen Hosp Psychiatry. 2009;31(3):206–19. doi: 10.1016/j.genhosppsych.2008.12.006. [DOI] [PubMed] [Google Scholar]
- 41.Roelofs PD, Deyo RA, Koes BW, Scholten RJ, van Tulder MW. Nonsteroidal anti-inflammatory drugs for low back pain: an updated Cochrane review. Spine (Phila Pa 1976) 2008;33(16):1766–74. doi: 10.1097/BRS.0b013e31817e69d3. [DOI] [PubMed] [Google Scholar]
- 42.Zerbini C, Ozturk ZE, Grifka J, Maini M, Nilganuwong S, Morales R, et al. Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study. Curr Med Res Opin. 2005;21(12):2037–49. doi: 10.1185/030079905X75069. [DOI] [PubMed] [Google Scholar]
- 43.Chung JW, Zeng Y, Wong TK. Drug therapy for the treatment of chronic nonspecific low back pain: systematic review and meta-analysis. Pain Physician. 2013;16(6):E685–704. [PubMed] [Google Scholar]
- 44.Malskat WS, Knulst AC, Bruijnzeel-Koomen CA, Rockmann H. Tolerance to alternative cyclooxygenase-2 inhibitors in nonsteroidal anti-inflammatory drug hypersensitive patients. Clin Transl Allergy. 2013;3(1):2045–7022. doi: 10.1186/2045-7022-3-20. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Tofferi JK, Jackson JL, O’Malley PG. Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis. Arthritis Rheum. 2004;51(1):9–13. doi: 10.1002/art.20076. [DOI] [PubMed] [Google Scholar]
- 46.Moldofsky H, Harris HW, Archambault WT, Kwong T, Lederman S. Effects of bedtime very low dose cyclobenzaprine on symptoms and sleep physiology in patients with fibromyalgia syndrome: a double-blind randomized placebo-controlled study. J Rheumatol. 2011;38(12):2653–63. doi: 10.3899/jrheum.110194. [DOI] [PubMed] [Google Scholar]
- 47.Spence MM, Shin PJ, Lee EA, Gibbs NE. Risk of injury associated with skeletal muscle relaxant use in older adults. Ann Pharmacother. 2013;47(7-8):993–8. doi: 10.1345/aph.1R735. [DOI] [PubMed] [Google Scholar]
- 48.Wiffen PJ, Derry S, Moore RA, Aldington D, Cole P, Rice AS, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database Syst Rev. 2013;11(11) doi: 10.1002/14651858.CD010567.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Argoff CE, Backonja MM, Belgrade MJ, Bennett GJ, Clark MR, Cole BE, et al. Consensus guidelines: treatment planning and options. Diabetic peripheral neuropathic pain. Mayo Clin Proc. 2006;81(4 Suppl):S12–25. doi: 10.1016/s0025-6196(11)61475-4. [DOI] [PubMed] [Google Scholar]
- 50.Dworkin RH, O’Connor AB, Backonja M, Farrar JT, Finnerup NB, Jensen TS, et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain. 2007;132(3):237–51. doi: 10.1016/j.pain.2007.08.033. [DOI] [PubMed] [Google Scholar]
- 51.Hauser W, Bernardy K, Uceyler N, Sommer C. Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. Jama. 2009;301(2):198–209. doi: 10.1001/jama.2008.944. [DOI] [PubMed] [Google Scholar]
- 52.Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev. 2012;12(12) doi: 10.1002/14651858.CD008242.pub2. [DOI] [PubMed] [Google Scholar]
- 53.Kroenke K, Bair MJ, Damush TM, Wu J, Hoke S, Sutherland J, et al. Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial. Jama. 2009;301(20):2099–110. doi: 10.1001/jama.2009.723. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev. 2014;3(1) doi: 10.1002/14651858.CD007115.pub3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Zin CS, Nissen LM, Smith MT, O’Callaghan JP, Moore BJ. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–42. doi: 10.2165/00023210-200822050-00005. [DOI] [PubMed] [Google Scholar]
- 56.Frakes EP, Risser RC, Ball TD, Hochberg MC, Wohlreich MM. Duloxetine added to oral nonsteroidal anti-inflammatory drugs for treatment of knee pain due to osteoarthritis: results of a randomized, double-blind, placebo-controlled trial. Curr Med Res Opin. 2011;27(12):2361–72. doi: 10.1185/03007995.2011.633502. [DOI] [PubMed] [Google Scholar]
- 57.Abou-Raya S, Abou-Raya A, Helmii M. Duloxetine for the management of pain in older adults with knee osteoarthritis: randomised placebo-controlled trial. Age Ageing. 2012;41(5):646–52. doi: 10.1093/ageing/afs072. [DOI] [PubMed] [Google Scholar]
- 58.Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev. 2010;20(1) doi: 10.1002/14651858.CD006605.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Joseph H, Stancliff S, Langrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000;67(5-6):347–64. [PubMed] [Google Scholar]
- 60.Corkery JM, Schifano F, Ghodse AH, Oyefeso A. The effects of methadone and its role in fatalities. Hum Psychopharmacol. 2004;19(8):565–76. doi: 10.1002/hup.630. [DOI] [PubMed] [Google Scholar]
- 61.Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev. 2007;18(2) doi: 10.1002/14651858.CD004846.pub2. [DOI] [PubMed] [Google Scholar]
- 62.Argoff CE. Topical analgesics in the management of acute and chronic pain. Mayo Clin Proc. 2013;88(2):195–205. doi: 10.1016/j.mayocp.2012.11.015. [DOI] [PubMed] [Google Scholar]
- 63.Mason L, Moore RA, Derry S, Edwards JE, McQuay HJ. Systematic review of topical capsaicin for the treatment of chronic pain. Bmj. 2004;328(7446):19. doi: 10.1136/bmj.38042.506748.EE. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Haroutiunian S, Drennan DA, Lipman AG. Topical NSAID therapy for musculoskeletal pain. Pain Med. 2010;11(4):535–49. doi: 10.1111/j.1526-4637.2010.00809.x. [DOI] [PubMed] [Google Scholar]
- 65.Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;12(9) doi: 10.1002/14651858.CD007400.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Deare JC, Zheng Z, Xue CC, Liu JP, Shang J, Scott SW, et al. Acupuncture for treating fibromyalgia. Cochrane Database Syst Rev. 2013;31(5) doi: 10.1002/14651858.CD007070.pub2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Vickers AJ, Cronin AM, Maschino AC, Lewith G, MacPherson H, Foster NE, et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med. 2012;172(19):1444–53. doi: 10.1001/archinternmed.2012.3654. [DOI] [PMC free article] [PubMed] [Google Scholar]
- *68.Cherkin DC, Sherman KJ, Avins AL, Erro JH, Ichikawa L, Barlow WE, et al. A randomized trial comparing acupuncture, simulated acupuncture, and usual care for chronic low back pain. Arch Intern Med. 2009;169(9):858–66. doi: 10.1001/archinternmed.2009.65. This randomized trial reports that patients with chronic back pain who received acupuncture had greater improvements in back-related dysfunction, and that these improvements were present 1 year later
- 69.Zheng Z, Guo RJ, Helme RD, Muir A, Da Costa C, Xue CC. The effect of electroacupuncture on opioid-like medication consumption by chronic pain patients: a pilot randomized controlled clinical trial. Eur J Pain. 2008;12(5):671–6. doi: 10.1016/j.ejpain.2007.10.003. [DOI] [PubMed] [Google Scholar]
- 70.Windmill J, Fisher E, Eccleston C, Derry S, Stannard C, Knaggs R, et al. Interventions for the reduction of prescribed opioid use in chronic non-cancer pain. Cochrane Database Syst Rev. 2013;1(9) doi: 10.1002/14651858.CD010323.pub2. [DOI] [PubMed] [Google Scholar]
- 71.Bernardy K, Fuber N, Kollner V, Hauser W. Efficacy of cognitive-behavioral therapies in fibromyalgia syndrome - a systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2010;37(10):1991–2005. doi: 10.3899/jrheum.100104. [DOI] [PubMed] [Google Scholar]
- 72.Lauche R, Cramer H, Hauser W, Dobos G, Langhorst J. A systematic review and meta-analysis of qigong for the fibromyalgia syndrome. Evid Based Complement Alternat Med. 2013;635182(10):31. doi: 10.1155/2013/635182. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73.Kumar S, Beaton K, Hughes T. The effectiveness of massage therapy for the treatment of nonspecific low back pain: a systematic review of systematic reviews. Int J Gen Med. 2013 Sep 4;6:733–741. doi: 10.2147/IJGM.S50243. eCollection 2013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Cherkin DC, Sherman KJ, Kahn J, Wellman R, Cook AJ, Johnson E, et al. A comparison of the effects of 2 types of massage and usual care on chronic low back pain: a randomized, controlled trial. Ann Intern Med. 2011;155(1):1–9. doi: 10.1059/0003-4819-155-1-201107050-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75.Scascighini L, Toma V, Dober-Spielmann S, Sprott H. Multidisciplinary treatment for chronic pain: a systematic review of interventions and outcomes. Rheumatology. 2008;47(5):670–8. doi: 10.1093/rheumatology/ken021. [DOI] [PubMed] [Google Scholar]
- 76.Karjalainen K, Malmivaara A, van Tulder M, Roine R, Jauhiainen M, Hurri H, et al. Multidisciplinary rehabilitation for fibromyalgia and musculoskeletal pain in working age adults. Cochrane Database Syst Rev. 2000;2 doi: 10.1002/14651858.CD001984. [DOI] [PMC free article] [PubMed] [Google Scholar]